2015-17年拉丁美洲SOAR抗生素耐药调查:基于CLSI、EUCAST(剂量特异性)和PK/PD折点的数据
该研究分析了2015-17年阿根廷、智利和哥斯达黎加社区获得性呼吸道感染中分离的170株肺炎链球菌和218株流感嗜血杆菌,采用CLSI微量肉汤稀释法测定MIC,并分别按CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。结果显示流感嗜血杆菌敏感性普遍较高,而肺炎链球菌敏感性因国家和折点而异,尤其头孢克洛;不同EUCAST剂量折点首次量化了提高剂量对敏感性的影响。
要点
- 拉丁美洲流感嗜血杆菌对阿莫西林/克拉维酸(高剂量)、头孢克肟、头孢泊肟、头孢曲松和氟喹诺酮类敏感性>90%。
- 阿根廷和智利肺炎链球菌对青霉素非敏感率分别约1/3和2/3(CLSI口服或EUCAST低剂量IV折点),但多数(≥89%)对CLSI IV或EUCAST高剂量折点敏感。
- 肺炎链球菌敏感性因国家和折点而异,智利分离株对多种抗生素的CLSI敏感性显著低于阿根廷(P<0.05)。
核心结论
- 流感嗜血杆菌分离株抗生素敏感性普遍较高,但肺炎链球菌敏感性因国家和所用折点而异,尤其头孢克洛。
研究设计与样本
- 2015-17年从阿根廷、智利和哥斯达黎加五个中心收集170株肺炎链球菌和218株流感嗜血杆菌。
- 采用CLSI微量肉汤稀释法测定MIC,并分别按CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。
主要发现
- 哥斯达黎加肺炎链球菌仅2株,仅纳入青霉素敏感性分析,排除后续国家分析。
- 阿根廷和智利肺炎链球菌对青霉素非敏感率分别约1/3和2/3(CLSI口服或EUCAST低剂量IV折点),但多数(≥89%)对CLSI IV或EUCAST高剂量折点敏感。
- 阿根廷肺炎链球菌对多数其他抗生素敏感率约≥80%,除外头孢克洛(所有折点)、头孢克肟(PK/PD折点)、头孢呋辛(EUCAST折点)和甲氧苄啶/磺胺甲噁唑(CLSI和PK/PD折点)。
- 智利肺炎链球菌对多种抗生素的CLSI敏感性显著低于阿根廷(P<0.05)。
- 拉丁美洲流感嗜血杆菌对阿莫西林/克拉维酸(高剂量)、头孢克肟、头孢泊肟、头孢曲松和氟喹诺酮类敏感性>90%(无论折点)。
关键数值与推荐
- 肺炎链球菌对青霉素非敏感率:阿根廷约1/3,智利约2/3(CLSI口服或EUCAST低剂量IV折点)。
- 肺炎链球菌对青霉素敏感率≥89%(CLSI IV或EUCAST高剂量折点)。
- 流感嗜血杆菌对阿莫西林/克拉维酸(高剂量)、头孢克肟、头孢泊肟、头孢曲松和氟喹诺酮类敏感性>90%。
- 智利与阿根廷肺炎链球菌CLSI敏感性差异P<0.05。
临床怎么用
- 经验性治疗细菌性感染时需考虑国家差异和折点选择对肺炎链球菌敏感性的影响。
- 流感嗜血杆菌对多数测试药物敏感性高,但肺炎链球菌尤其头孢克洛需参考当地药敏数据。
- EUCAST剂量特异性折点可量化提高剂量对敏感性的影响,辅助剂量决策。
局限性
- 哥斯达黎加肺炎链球菌分离株仅2株,无法纳入国家间比较。
- 样本来自五个中心,可能不能完全代表整个国家。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2015-17 from Argentina, Chile and Costa Rica. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 170 S. pneumoniae and 218 H. influenzae isolates were collected at five centres in Argentina, Chile and Costa Rica in 2015-17. Small S. pneumoniae isolate numbers from Costa Rica (n = 2) meant that these could only be included in the penicillin susceptibility analysis; they were excluded from further country analyses. Around one-third of pneumococcal isolates from Argentina and two-thirds from Chile were non-susceptible to penicillin by CLSI oral or EUCAST low-dose IV breakpoints, but most (≥89%) were susceptible by CLSI IV or EUCAST high-dose breakpoints. Amongst pneumococci from Argentina, about 80% or more were susceptible to most other antibiotics except cefaclor (all breakpoints), cefixime (PK/PD breakpoints), cefuroxime (EUCAST breakpoints) and trimethoprim/sulfamethoxazole (CLSI and PK/PD breakpoints). S. pneumoniae isolates from Chile showed significantly lower susceptibility (P < 0.05) using CLSI breakpoints compared with those from Argentina for many of the antibiotics tested. Among isolates of H. influenzae from Latin America, more than 90% were susceptible to amoxicillin/clavulanic acid (high dose), cefixime, cefpodoxime, ceftriaxone and fluoroquinolones, irrespective of the breakpoints used. The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Antibiotic susceptibility of H. influenzae isolates was generally high in the Latin American countries studied; however, susceptibility profiles varied for S. pneumoniae by country and depending on the breakpoints used, especially for cefaclor. These factors are important in decision making for empirical therapy of bacterial infections.
引用
- Torumkuney D, Smayevsky J, Relloso MS, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in Latin America (Argentina, Chile and Costa Rica): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337593. doi:10.1093/jac/dkaa083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。